

Supplementary Table 1. Patient Characteristics

|           | Sex, age (y) | Disease duration, extent of disease | Prior therapy                       | Severe disease features   | Days of IV steroids before initiating tofacitinib | Colectomy                          | Long-term therapy           | Duration of follow-up (mo) |
|-----------|--------------|-------------------------------------|-------------------------------------|---|---|------------------------------------|-----------------------------|----------------------------|
| Patient 1 | Male, 34     | 2 wk, left-sided colitis            | None                                | 12–15 bloody BMs/d<br>Pulse 99 bpm<br>ESR 100 mm/h<br>CRP 174 mg/L<br>Albumin 3.1 g/dL<br>Severe endoscopic features<br>T&W score = 31%   | 1 d   | No                                 | Infliximab                  | 18                         |
| Patient 2 | Male, 51     | 1 y, pancolitis                     | AZA, infliximab<br>chronic steroids | 12–15 bloody BMs/d<br>ESR 46 mm/h<br>CRP 30 mg/L<br>Albumin 2.8 g/dL<br>Severe endoscopic features<br>Chronic oral steroids<br>Prior biologic failure<br>T&W score = 9%   | 1 d   | Yes, at 6 mo for<br>dysplasia      | Tofacitinib                 | 18                         |
| Patient 3 | Female, 38   | 2 mo, pancolitis                    | Chronic steroids                    | Pulse 115 bpm<br>Reported weight loss<br>ESR 35 mm/h<br>CRP 242 mg/L<br>Albumin 2.5 g/dL<br>Severe endoscopic features<br>Chronic oral steroids<br>Prolonged IV steroids<br>Colonic dilation<br>T&W score = 31%<br>Travis 85% | 7 d   | Yes, because<br>of medical failure | N/A                         | 13                         |
| Patient 4 | Male, 19     | 13 y, pancolitis                    | Infliximab,<br>adalimumab           | 6 bloody BMs/d<br>Reported weight loss<br>Reported fevers at home<br>ESR 63 mm/h<br>CRP 89 mg/L<br>Albumin 3.2 g/dL<br>Severe endoscopic features<br>Prior biologic failure<br>Steroid contraindication<br>T&W score = 40%    | N/A   | No                                 | Tofacitinib,<br>vedolizumab | 2                          |

NOTE. T&W calculated based on >6 bloody bowel movements/d and one or more of temperature >37.5°C, pulse >90 bpm, hemoglobin <10.5 g/dL, ESR >30 mm/h. If +1 additional criterion, risk of colectomy = 9%; if +2 risk = 31%; if +3 or +4 risk >40%.<sup>6</sup> Travis Index indicates an 85% risk for colectomy if >8 BMs/d or (>2 BMs/d and CRP >45 mg/L) at day 3.<sup>7</sup> AZA, azathioprine; BM, bowel movement; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IV, intravenous; NA, not applicable; T&W, Truelove and Witt's criteria.